Kar Mitra, Siddiqui Tasneem, Dubey Akanksha, Hashim Zia, Sahu Chinmoy, Ghoshal Ujjala
Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh-226014, India.
Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh -226014, India.
Access Microbiol. 2023 Jun 22;5(6). doi: 10.1099/acmi.0.000514.v3. eCollection 2023.
Patients with coronavirus disease-2019 (COVID-19) are prone to develop respiratory bacterial infections irrespective of their need for mechanical ventilatory support.
HYPOTHESIS/GAP STATEMENT: Information about the incidence of concomitant respiratory bacterial infections in COVID- 19 patients from India is limited.
This study aimed to determine the incidence of concomitant respiratory bacterial pathogens and their drug resistance in these patients.
A prospective study was performed by including patients who were admitted to our tertiary care centre from March 2021 to May 2021 to evaluate secondary bacterial respiratory co-infections in patients via real-time PCR (RT-PCR)-confirmed cases of COVID-19 disease caused by SARS CoV-2.
Sixty-nine culture-positive respiratory samples from patients with COVID-19 were incorporated into this study. The most commonly isolated bacterial microorganisms were (23 samples, 33.33 %) and (15, 21.73 %), followed by (13, 18.84 %). Among the microorganisms isolated, 41 (59.4 %) were multidrug-resistant (MDR) and nine (13 %) were extensively drug-resistant (XDR). Among the Gram-negative bacteria isolated, showed high drug resistance. Fifty carbapenem-resistant microorganisms were isolated from the patients included in our study. Concerning the hospital stay of the patients enrolled, there was an increased length of intensive care unit stay, which was 22.25±15.42 days among patients needing mechanical ventilation in comparison to 5.39±9.57 days in patients on ambient air or low/high-flow oxygen.
COVID-19 patients need increased length of hospitalization and have a high incidence of secondary respiratory bacterial infections and high antimicrobial drug resistance.
2019年冠状病毒病（COVID-19）患者无论是否需要机械通气支持，都容易发生呼吸道细菌感染。
假设/差距陈述：来自印度的COVID-19患者并发呼吸道细菌感染的发生率信息有限。
本研究旨在确定这些患者中并发呼吸道细菌病原体的发生率及其耐药性。
进行了一项前瞻性研究，纳入了2021年3月至2021年5月入住我们三级护理中心的患者，通过实时荧光定量聚合酶链反应（RT-PCR）确诊由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的COVID-19疾病，以评估患者的继发性细菌性呼吸道合并感染。
本研究纳入了69份来自COVID-19患者的培养阳性呼吸道样本。最常分离出的细菌微生物是[具体细菌1]（23份样本，33.33%）和[具体细菌2]（15份，21.73%），其次是[具体细菌3]（13份，18.84%）。在分离出的微生物中，41种（59.4%）为多重耐药（MDR），9种（13%）为广泛耐药（XDR）。在分离出的革兰氏阴性菌中，[具体细菌4]显示出高耐药性。从我们研究纳入的患者中分离出50种耐碳青霉烯类微生物。关于纳入患者的住院时间，重症监护病房住院时间延长，需要机械通气的患者平均为22.25±15.42天，而接受环境空气或低/高流量氧气治疗的患者为5.39±9.57天。
COVID-19患者需要更长的住院时间，继发性呼吸道细菌感染的发生率高，抗菌药物耐药性也高。
